women were discharged within 12 months of being treated for a high grade lesion (72.0% of all women treated for a high grade lesion). The proportion of women with follow-up has decreased slightly overall (from Trends 76.2% to 75.4% for colposcopy, and from 74.9% to 74.3% for both cytology and colposcopy). One DHB met the target of 90% of women having colposcopy and cytology within nine months of treatment, compared to two DHBs in the previous report. The proportion of women discharged appropriately to their smear-taker by 12 months has increased (82.9% in the previous report; 83.5% in the current report). The number of DHBs meeting the target of 90% increased from five to eight. Comments Since this indicator relies on colposcopy data in the NCSP Register, there is the possibility that incomplete reporting of colposcopy visits has led to an underestimate of the number of women with follow-up colposcopy visits and the number discharged in a given time period. The data used in this analysis was extracted from the NCSP Register in mid-February 2017. The target that 90% or more of women treated for CIN 2 or 3 should be discharged back to the smear-taker as appropriate was assessed in this monitoring report, based on guidance from the NCSP Advisory Group as to when discharge would be appropriate. However, it should be noted that neither the 2008 NCSP Guidelines for Cervical Screening in New Zealand nor the 2013 Colposcopy Standards themselves provide explicit guidance for when discharge back to the smear-taker is appropriate. In some circumstances, women may be treated within one DHB, but referred to another DHB for follow-up. This information is not always recorded in the NCSP Register however, and for clarity in this report, women remain assigned to the DHB where their treatment was performed. However, this measure does take into account all follow-up visits which women attend, regardless of the DHB in which they occurred. Figure 86 - Percentage of women treated with colposcopy, and both colposcopy and cytology, within nine months post-treatment Figure 87 - Percentage of women discharged appropriately within 12 months of treatment Indicator 8 – HPV tests The indicators report on the use of HPV testing. At present, they incorporate the following indicators:
women were discharged within 12 months of being treated for a high grade lesion (72.0% of all women treated for a high grade lesion). Trends The proportion of women with follow-up has decreased slightly overall (from 76.2% to 75.4% for colposcopy, and from 74.9% to 74.3% for both cytology and colposcopy). One DHB met the target of 90% of women having colposcopy and cytology within nine months of treatment, compared to two DHBs in the previous report. The proportion of women discharged appropriately to their smear-taker by 12 months has increased (82.9% in the previous report; 83.5% in the current report). The number of DHBs meeting the target of 90% increased from five to eight. Comments Since this indicator relies on colposcopy data in the NCSP Register, there is the possibility that incomplete reporting of colposcopy visits has led to an underestimate of the number of women with follow-up colposcopy visits and the number discharged in a given time period. The data used in this analysis was extracted from the NCSP Register in mid-February 2017. The target that 90% or more of women treated for CIN 2 or 3 should be discharged back to the smear-taker as appropriate was assessed in this monitoring report, based on guidance from the NCSP Advisory Group as to when discharge would be appropriate. However, it should be noted that neither the 2008 NCSP Guidelines for Cervical Screening in New Zealand nor the 2013 Colposcopy Standards themselves provide explicit guidance for when discharge back to the smear-taker is appropriate. In some circumstances, women may be treated within one DHB, but referred to another DHB for follow-up. This information is not always recorded in the NCSP Register however, and for clarity in this report, women remain assigned to the DHB where their treatment was performed. However, this measure does take into account all follow-up visits which women attend, regardless of the DHB in which they occurred. Figure 86 - Percentage of women treated with colposcopy, and both colposcopy and cytology, within nine months post-treatment Figure 87 - Percentage of women discharged appropriately within 12 months of treatment Indicator 8 – HPV tests The indicators report on the use of HPV testing. At present, they incorporate the following indicators: